Consensus AtriCure, Inc.

Stocks

ATRC

US04963C2098

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 06:00:00 03/07/26 am AEST			5-day change	1st Jan Change
31.79 ^USD	+6.93%		+13.01%	-19.64%

29/06	AtriCure, Inc.(NasdaqGM:ATRC) added to Russell 2000 Defensive Index	CI
29/06	AtriCure, Inc.(NasdaqGM:ATRC) added to Russell 2000 Growth-Defensive Index	CI

Evolution of the Average Target: AtriCure, Inc.

Evolution of the Target Price: AtriCure, Inc.

Changes in Analyst Recommendations: AtriCure, Inc.

5c2d0740fe726337f6c6ad.9a_e8fk1ikkW6ggNhtGN7dsQ6jW1TsVNFi6wFEuhUxE.gvy7nM5PwyBGx0FI7en_pu1o0gfTDPcZIRv5WhvZOVeD5rvEj2H7PWbHRQ~fc053bc65a11a94e6eba1ea7f698f4f3

Analysts' recommendations: AtriCure, Inc.

19/02	UBS Adjusts AtriCure Price Target to $55 From $60, Maintains Buy Rating	MT
18/02	Oppenheimer Downgrades AtriCure to Market Perform From Outperform	MT
12/02	AtriCure Shares Fall After JPMorgan Downgrade	MT
12/02	Top Midday Decliners	MT
11/02	JPMorgan Downgrades AtriCure to Neutral From Overweight, Adjusts PT to $36 From $48	MT
30/07/25	Needham Raises Price Target on AtriCure to $45 From $44, Keeps Buy Rating	MT
30/07/25	AtriCure Q2 revenue beats estimates	RE
30/04/25	UBS Adjusts Price Target on AtriCure to $58 From $60, Maintains Buy Rating	MT
28/03/25	Canaccord Genuity Adjusts Price Target on AtriCure to $52 From $66, Maintains Buy Rating	MT
14/02/25	Oppenheimer Adjusts AtriCure Price Target to $45 From $36, Maintains Outperform Rating	MT
31/10/24	UBS Adjusts Price Target on AtriCure to $40 From $35, Maintains Buy Rating	MT
31/07/24	Needham Adjusts AtriCure's Price Target to $34 From $40, Keeps Buy Rating	MT
02/05/24	Needham Lowers AtriCure's PT to $40 From $46 Due to Peer Multiple Contraction, Keeps Buy Rating	MT
23/04/24	Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32	MT
17/02/24	UBS Adjusts AtriCure Price Target to $58 From $57, Maintains Buy Rating	MT
17/02/24	Stifel Adjusts Price Target on AtriCure to $42 From $50, Maintains Buy Rating	MT
17/02/24	Needham Adjusts Price Target on AtriCure to $46 From $44, Keeps Buy Rating	MT
23/01/24	UBS Adjusts AtriCure Price Target to $57 From $56, Maintains Buy Rating	MT
23/10/23	JMP Securities Initiates AtriCure With Market Outperform Rating, Price Target is $60	MT
30/09/23	UBS Initiates AtriCure With Buy Rating, Price Target is $56	MT
26/07/23	Needham Adjusts Price Target on AtriCure to $68 From $60, Maintains Buy Rating	MT
03/05/23	Needham Adjusts Price Target on AtriCure to $60 From $58, Maintains Buy Rating	MT
23/02/23	BTIG Lowers Price Target on AtriCure to $55 From $65, Maintains Buy Rating	MT
23/02/23	Stifel Adjusts Price Target on AtriCure to $48 From $55, Maintains Buy Rating	MT
23/02/23	Canaccord Genuity Adjusts Price Target on AtriCure to $74 From $81, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ATRICURE, INC.					+47.85%
	ABBOTT LABORATORIES					+22.35%
	MEDTRONIC PLC					+17.53%
	CENCORA, INC.					+18.38%
	HOYA CORPORATION					+18.72%
	BECTON, DICKINSON AND COMPANY					+12.44%
	MEDLINE INC.					+18.43%
	DEXCOM, INC.					+19.64%
	WEST PHARMACEUTICAL SERVICES, INC.					-1.12%
	STERIS PLC					+17.72%
	Average					+19.19%
	Weighted average by Cap.					+18.18%